Journal profile · Endocrinology & Metabolism
Current Opinion in Lipidology
ISSN 0957-9672 · eISSN 1473-6535 · Lippincott Williams and Wilkins Ltd. · ENGLAND · Bimonthly
Current Opinion in Lipidology: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 4.62; JCR Q1 (journal website); hybrid open access; review 6–12 weeks (community reports); community-reported acceptance: moderate; 42 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Current Opinion in Lipidology is published by Lippincott Williams and Wilkins Ltd. and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lipoproteins and Cardiovascular Health, Diabetes, Cardiovascular Risks, and Lipoproteins and Atherosclerosis and Cardiovascular Diseases, together about 40.8% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
With its easy-to-digest reviews on important advances in world literature, Current Opinion in Lipidology offers expert evaluation on a wide range of topics from six key disciplines including nutrition and metabolism, genetics and molecular biology, and hyperlipidaemia and cardiovascular disease. Published bimonthly, each issue covers in detail the most pertinent advances in these fields from the previous year. This is supplemented by a section of Bimonthly Updates, which deliver an insight into new developments at the cutting edge of the disciplines covered in the journal.
Source: LetPub
Research area (LetPub): Endocrinology & Metabolism
Editor-in-chief Robert A. HegelePublisher website
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lipoproteins and Cardiovascular HealthMedicine17.9%
- Diabetes, Cardiovascular Risks, and LipoproteinsMedicine15%
- Atherosclerosis and Cardiovascular DiseasesImmunology and Microbiology7.9%
- Cancer, Lipids, and MetabolismBiochemistry, Genetics and Molecular Biology7.4%
- Cholesterol and Lipid MetabolismMedicine7%
- Peroxisome Proliferator-Activated ReceptorsBiochemistry, Genetics and Molecular Biology5.2%
- Lipid metabolism and disordersMedicine4.9%
- Adipokines, Inflammation, and Metabolic DiseasesMedicine4.1%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 3 |
Top journal: noReview journal: yes
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Biochemistry & Molecular Biology | Zone 2 |
| Minor | Endocrinology & Metabolism | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Biochemistry & Molecular Biology | Zone 3 |
| Minor | Endocrinology & Metabolism | Zone 3 |
| Minor | Peripheral Vascular Disease | Zone 3 |
Top journal: noReview journal: yes
JCR / CiteScore quartiles on the journal's website
- JCR Q2 · BIOCHEMISTRY & MOLECULAR BIOLOGY · rank 103/328
- JCR Q2 · ENDOCRINOLOGY & METABOLISM · rank 58/198
- JCR Q1 · PERIPHERAL VASCULAR DISEASE · rank 22/100
Publisher-reported: JCR figures are Clarivate's and CiteScore figures Scopus's to confirm; both are a different system from the CAS zones.Publisher website
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 4.62LetPub ·
- Impact factor (publisher)
- 4.5Publisher website ·
- CiteScore 2026-06
- 7.5LetPub ·
- SJR 2026-06
- 1.35LetPub ·
- SNIP 2026-06
- 1.2LetPub ·
- h-index
- 116LetPub ·
- h-index
- 155OpenAlex ·
- i10-index
- 1,768OpenAlex ·
- 2-year mean citedness
- 5.09OpenAlex ·
- Self-citation rate
- 4.4%LetPub ·
- Share of gold OA articles
- 24%LetPub ·
Volume
- Articles per year
- 43LetPub ·
Articles by year OpenAlex count · 3,504 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 32 | 8 | 9 |
| 2025 | 42 | 13 | 158 |
| 2024 | 48 | 22 | 454 |
| 2023 | 48 | 14 | 469 |
| 2022 | 42 | 15 | 900 |
| 2021 | 74 | 25 | 1,251 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
- Average review time (community reports)
- 6–12 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
No source has fee information yet; check the journal's website.
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Lippincott Williams and Wilkins Ltd.
- Country or region
- ENGLAND
- Language
- English
- Frequency
- Bimonthly
- ISSN
- 0957-9672
- Electronic ISSN
- 1473-6535
- Latest issue on the website
- Volume 37, Issue 5 (October 2026)
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about Current Opinion in Lipidology
What CAS zone is Current Opinion in Lipidology in?
In the 2025 upgraded edition of the CAS Journal Ranking, Current Opinion in Lipidology is in Zone 3 of Medicine, and in Zone 3 of the minor category Biochemistry & Molecular Biology / Endocrinology & Metabolism / Peripheral Vascular Disease. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Current Opinion in Lipidology?
The latest impact factor listed by LetPub is 4.62; CiteScore 7.5, h-index 155.
How long does peer review take at Current Opinion in Lipidology?
Authors report an average review time of 6–12 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What JCR quartile is Current Opinion in Lipidology in?
The journal's website gives JCR Q1; by category, BIOCHEMISTRY & MOLECULAR BIOLOGY Q2 (103/328), ENDOCRINOLOGY & METABOLISM Q2 (58/198), PERIPHERAL VASCULAR DISEASE Q1 (22/100). JCR quartiles are Clarivate's to confirm and a different system from the CAS zones; in the CAS ranking the journal is in Zone 3 of Medicine.
Which databases index Current Opinion in Lipidology?
According to LetPub and DOAJ records, Current Opinion in Lipidology is indexed in SCIE and Scopus.
Is Current Opinion in Lipidology open access, and what is the APC?
Current Opinion in Lipidology is a hybrid journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .